Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 8/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.73 |
| ▸ | HTR1B | P28222 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.65 |
| ▸ | HTR3B | O95264 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319425 | 0.93 | HTR1D (1.00) | MAPK14LCKHTR1DSLC6A4HTR1B | |
| SCHEMBL7795174 | 0.90 | HTR1D (0.85) | MAPK14LCKHTR1DSLC6A4HTR1B | |
| SCHEMBL7801646 | 0.85 | HTR1D (0.87) | MAPK14LCKHTR1DSLC6A4HTR1B | |
| SCHEMBL4864546 | 0.85 | MAPK14 (0.78) | MAPK14LCKHTR1DSLC6A4CSF1R | |
| SCHEMBL6487595 | 0.83 | MAPK14 (1.00) | MAPK14LCKHTR1DSLC6A4HTR1B | |
| SCHEMBL4856455 | 0.83 | MAPK14 (0.74) | MAPK14LCKHTR1DSLC6A4CSF1R | |
| SCHEMBL7880723 | 0.82 | HTR1D (1.00) | MAPK14LCKHTR1DSLC6A4HTR1B | |
| SCHEMBL7795200 | 0.82 | HTR1D (0.83) | MAPK14LCKHTR1DSLC6A4HTR1B | |
| SCHEMBL7801558 | 0.81 | HTR1D (0.78) | MAPK14LCKHTR1DSLC6A4HTR1B | |
| SCHEMBL9435227 | 0.81 | HTR1D (0.78) | MAPK14LCKHTR1DSLC6A4HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | claimed |
| EP-1436269-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | claimed |
| WO-2003033482-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | claimed |
| EP-0533268-B1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LTD (GB) | 2001-08-16 | — | — | EP | claimed |
| EP-0533268-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | claimed |
| EP-1436269-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033482-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| EP-0533268-B1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LTD (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-5510350-A | USEFUL IN TREATMENT OR PROPHYLAXIS OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1996-04-23 | — | — | US | disclosed |
| US-5340810-A | Useful in the treatment and prophylaxis of depression and other disorders of the central nervous system | GLAXO GROUP LIMITED (GB) | 1994-08-23 | — | — | US | disclosed |
| EP-0533268-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | MAPK14 7/4885LCK 56/4885HTR1D 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.